Login
$MRKR
$0.82 -$0.01 (1.04%) After hours

$MRKR 8-K SEC Filings

Filed On Filing
19 Oct 2026 8-K: Other Events

Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform

04 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF MARKER THERAPEUTICS, INC.

19 Mar 2026 8-K: Results of Operations and Financial Condition

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses

09 Feb 2026 8-K: Shareholder Director Nominations

On February 9, 2026, the Board of Directors of Marker Therapeutics, Inc. (the “Company”) determined it is in the best interest of the Company to schedule Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for May 1...

14 Nov 2025 8-K: Results of Operations and Financial Condition

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma

05 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Houston, TX — November 5, 2025 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and s...

06 Oct 2025 8-K: Other Events

Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment

26 Aug 2025 8-K: Regulation FD Disclosure

MARKER THERAPEUTICS CORPORATE PRESENTATION August 26, 2025 NASDAQ: MRKR

12 Aug 2025 8-K: Changes in Registrant's Certifying Accountant

We have read the statements made by Marker Therapeutics, Inc. under Item 4.01 of its Form 8-K dated August 7, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with oth...

17 Jun 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

09 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 6, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed wi...

20 May 2025 8-K: Other Events

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

31 Mar 2025 8-K: Results of Operations and Financial Condition

Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses

27 Mar 2025 8-K: Submission of Matters to a Vote of Security Holders

On March 21, 2025, the Company held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the stockholders considered one proposal, which is described in more detail in the Company’s definitive proxy statemen...

19 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers.

30 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers.

23 Dec 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 19, 2024, is by and among Marker Therapeutics, Inc., a Delaware corporation with offices located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77...

19 Dec 2024 8-K: Entry into a Material Definitive Agreement; Other Events

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 19, 2024, is by and among Marker Therapeutics, Inc., a Delaware corporation with offices located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77...

17 Dec 2024 8-K: Other Events

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

14 Nov 2024 8-K: Results of Operations and Financial Condition

Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support